Cargando…
Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer
First-line PD-1 blockade plus chemotherapy significantly improves the survival benefits in late-stage gastric cancer (GC) patients. However, the pathological response rate and effects on the immune microenvironment of neoadjuvant PD-1 blockade plus chemotherapy in patients with cTNM-stage III GC rem...
Autores principales: | Tang, Xiaohuan, Li, Mengyuan, Wu, Xiaolong, Guo, Ting, Zhang, Li, Tang, Lei, Jia, Fangzhou, Hu, Ying, Zhang, Yan, Xing, Xiaofang, Shan, Fei, Gao, Xiangyu, Li, Ziyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578498/ https://www.ncbi.nlm.nih.gov/pubmed/36268179 http://dx.doi.org/10.1080/2162402X.2022.2135819 |
Ejemplares similares
-
Focal Adhesion-Related Signatures Predict the Treatment Efficacy of Chemotherapy and Prognosis in Patients with Gastric Cancer
por: Tang, Xiaohuan, et al.
Publicado: (2022) -
Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023) -
Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study
por: Zhang, Xuchen, et al.
Publicado: (2023) -
Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer
por: Tang, Xiaohuan, et al.
Publicado: (2022) -
Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)